Outcomes In Patients With 4-10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study
G.J. Kim(Duke Medical Center), John P. Kirkpatrick(Duke University), James E. Herndon(Duke University), Carey K. Anders(Duke University), W Giles(Duke Medical Center), Karen Allen, Peter E. Fecci(University of Colorado Anschutz Medical Campus), Jordan A. Torok(Duke Medical Center), Junzo Chino(Duke University), Joshua N. Sampson(National Institutes of Health), Evan Buckley, Justus Adamson(Duke Medical Center), T. Dale(Duke Medical Center), Z. Wang(Duke Medical Center), F Yin(Duke Kunshan University), Lori Vales Lay(Duke Medical Center), Chris R. Kelsey(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), A. Rodrigues(Duke Medical Center), Scott Floyd(Duke University)
International Journal of Radiation Oncology*Biology*Physics
October 23, 2020
Cited by 12
Related Papers
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
|International Journal of Radiation Oncology*Biology*Physics|2009|984
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917